This study identifies an H3K18la-KIF20A/PD-L1 axis as a key metabolic-epigenetic checkpoint, highlighting glycolysis targeting as a promising strategy to enhance anti-PD-1 responses in HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.